Akero Therapeutics' efruxifermin shows strong potential in MASH, especially compensated cirrhosis. Click here to find out why ...

Retailers are trying to navigate their way through economic uncertainty in 2025. Tariffs, inflation and lingering fears of a ...

The retailer's CEO attributed the results to weakness in discretionary spending, declining consumer confidence, uncertainty ...

The retailer’s comparable sales fell 3.8% in the latest quarter, a steeper drop than expected.

Gain insights from Target's Q1 2025 earnings call as management tackles sales declines, tariff impacts, and launches strategic changes to drive growth ...

The retailer’s sales fell short of expectations, and it slashed its full-year financial forecast, citing a “challenging” ...

Target shares sank 7% Wednesday morning after the retail giant lowered its full-year sales projection following mixed ...

Target now expects a “low single-digit [percentage] decline” in sales for the fiscal year; it previously forecast 1 percent ...

Sales at Target fell more than expected in the first quarter and the retailer warned they will slip for all of 2025 year as ...

Target's top boss warned that the company has been trying to navigate thought a highly challenging environment, which included President Trump's trade war with other nations.

Falling in line with actions seen by other big banks this year as tariff concerns bite, HSBC on Tuesday slashed its target for the U.S. equity-market benchmark SPX to 5,600 from 6,700, based on a ...

SOL price formed a bull flag, with a price target at $220 ... Solana also commands a 27.7% DEX volume market share, ahead of BNB Chains and Ethereum’s 18%. SOL price has formed a bull flag ...